Deepika Panday, MD
Endocrinology, Diabetes & Metabolism · San Tan Valley, AZNPI 1659829182
Payments from drug & device makers
Across 121 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$306
- BETA Bionics, Inc.$174
- Gilead$137
- Pfizer$135
- Lilly USA, LLC$131
- Sequel Med Tech, LLC$124
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,135100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 16 | $306 |
| BETA Bionics, Inc. | 13 | $174 |
| Gilead | 6 | $137 |
| Pfizer | 9 | $135 |
| Lilly USA, LLC | 7 | $131 |
| Sequel Med Tech, LLC | 4 | $124 |
| Boehringer Ingelheim | 7 | $123 |
| Medtronic | 7 | $115 |
| Radius Health, Inc. | 6 | $111 |
| AstraZeneca | 6 | $104 |
| AbbVie | 5 | $91 |
| Insulet Corporation | 4 | $66 |
| Tandem Diabetes Care, Inc. | 3 | $52 |
| Dexcom, Inc. | 3 | $51 |
| Corcept Therapeutics | 3 | $42 |
| Novo Nordisk | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Merck | 2 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Biogen | 1 | $21 |
| Mannkind Corporation | 1 | $20 |
| Novartis | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Cequr Corporation | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Amgen | 1 | $13 |
How this compares
$2,135 in reported general payments places this provider in the 45th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 199 | $348,506 |
| OzempicSemaglutide | 155 | $277,666 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 87 | $127,114 |
| JardianceEmpagliflozin | 112 | $124,553 |
| TrulicityDulaglutide | 45 | $75,278 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 29 | $47,413 |
| FarxigaDapagliflozin Propanediol | 35 | $43,702 |
| RybelsusSemaglutide | 15 | $28,565 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $27,925 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $25,224 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $23,000 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $21,898 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 37 | $13,899 |
| Repatha SureclickEvolocumab | 11 | $12,986 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 116 | $12,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $131 | $435,950288 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $33 | $314,021185 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $29 | $129,35298 claims |
| Boehringer IngelheimJardiance | $123 | $124,553112 claims |
| AstraZenecaFarxiga | $104 | $43,70235 claims |
| AbbVieSynthroid | $91 | $5,16752 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $2,107248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in San Tan Valley
- Kevin YuenPhoenix$733K
- Muhammad SethiTucson$670K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
- Peter ReavenPhoenix$142K
- Laura KnechtCave Creek$142K
- Andrea FerencziScottsdale$137K
- Stephen ThomsonTucson$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.